Cipla Palliative Care Centre, established in 1997 in Pune, has completed 15 years of operations and following the overwhelming response on the price cut received from the patients & their families and doctors, Cipla has announced another breakthrough price reduction in three additional anti-cancer drugs - Erlotinib (Erlocip), Docetaxel (Docetax) and Capecitabine (Capegard). These drugs are for the treatment of lung and pancreatic cancer, breast cancer, head & neck cancer, gastric cancer, bladder, colorectal and colon cancers.

The price of Erlocip-150, containing Erlotinib molecule, has been reduced by Rs.17,100 for 30 tablets to Rs.9,900 and that of Erlocip-100 by Rs.11,400 for 30 tablets to Rs.6,600. It also reduced price of Docetax 120 mg and 80 mg.by half to Rs.7,000 and Rs.5,000 respectively. The company revised price of Capegard 500 mg to Rs.600 from current price of Rs.1,200.

Today, it is one of the few centres in India offering the best-in class palliative care to cancer patients. The Centre provides free treatment and has cared for over 8,000 patients till date. It has also trained a large number of nurses in advanced palliative care. For more information on the Cipla Palliative Care and Training Centre.

Dr Y K Hamied, chairman and managing director, Cipla Ltd, said, “Continuing its contribution towards affordable and accessible treatment for patients, Cipla extends the work done in HIV/AIDS and Malaria to now include cancer, not only in India but globally.”

In continuation with its commitment to make medicines affordable and accessible, particularly in anti-cancer medication, in May 2012, Cipla announced a dramatic price cut in three major anti-cancer drugs - Sorafenib (Soranib), Gefitinib (Gefticip) and Temozolomide (Temoside).